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Current Issues Novel Therapies New cancer treatments continue to move away from traditional cytotoxic chemotherapy to more specific and targeted therapies. One of the many striking examples of successful targeted therapy came from the identification of the bcr-abl fusion protein, the driving oncogenic force in chronic myeloid leukaemia (CML). 1 Imatinib mesylate (Gleevec) was designed as a competitive inhibitor of the bcr-abl fusion protein, thus reversing the malignant CML phenotype. Although most other cancer types have more than one pathway involved, research is now focused on identifying critical up-or downregulated pathways and selectively targeting key molecules responsible for perpetuating the oncogenic state. One such promising target is survivin, a small 16.5kDa
protein belonging to the inhibitor-of-apoptosis (IAP) family. 2 Interest in survivin stems from its pattern of expression: it is upregulated in almost all tumour types while being minimally expressed in terminally differentiated tissues. 3 Moreover, it plays a key role in both apoptosis and control of cell-cycle progression, and in tumours its expression is associated with poorer prognosis and increased treatment resistance. 4 A number of strategies to inhibit survivin expression are being evaluated in the pre-clinical setting and some survivin-targeted therapies have now reached first-in-human trials. This article aims to review the role of survivin at a cellular and molecular level in normal and malignant tissues, the rationale for targeting the protein and the pre-clinical and early clinical data on survivin inhibitors.
Structure and Function of Survivin
The smallest member of the IAP family, survivin is composed of a single baculovirus IAP repeat (BIR) domain and an extended α-helical coiledcoil domain at the carboxy terminus 5 (see Figure 1) . It functions as a homodimer, requiring the BIR domain for dimerisation and recruitment of other proteins such as caspase 3, p21 and Cdk4. 6 Differential splicing of the survivin gene pre-messenger RNA (mRNA) yields five distinct proteins: survivin (wild-type), survivin-∆Ex3, survivin-2β, 7 survivin-3β 8 and survivin-2α. 9 While wild-type survivin is often the predominant transcript, these survivin variants have been shown to have distinct functions and be of prognostic significance, 10 e.g. delta Exon 3 and survivin-3β are cytoprotective, 11 while survivin-2α and survivin-2β are pro-apoptotic. 7 Delta Exon 3 has been associated with a poorer prognosis, higher stage or more aggressive disease in several tumour types, 12, 13 while low levels of survivin-2β correlate with high-stage gastric cancer 10 and poorer prognosis in non-small-cell lung cancer (NSCLC). 13 
Role of Survivin in Apoptosis
Many studies have shown that survivin opposes both intrinsic and extrinsic mediators of apoptosis. 4 Like most other IAPs, it acts upstream of effector caspases rather than through direct caspase inhibition. 14 In the cytosol, survivin associates with hepatitis B X-interacting protein (HBXIP) and the complex binds to pro-caspase 9, preventing its recruitment and activation by the apoptosome. 15 Another mechanism involves the sequestration of second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO). Smac/DIABLO is a mitochondrial pro-apoptotic signal that binds X-linked IAP (XIAP), thereby preventing apoptosis inhibition.
Survivin has been shown to prevent the release of Smac/DIABLO from the mitochondria, leaving XIAP free to inhibit caspase activity. 16 Lastly, survivin can also bind directly to XIAP, stabilising it against degradation and resulting in inhibition of apoptosis.
Role of Survivin in the Cell Cycle
Survivin is involved with all stages of the cell cycle from spindle formation to chromosome separation and cytokinesis. It functions, in part, as a member of the chromosomal passenger complex (CPC). 18 In addition to survivin, the CPC comprises Aurora kinase B (AURKB) and borealin and inner centromere protein (INCENP), and has a major role in several aspects of cell-cycle control including spindle formation, kinetochore-microtubule attachments, the spindle checkpoint and cytokinesis. 18, 19 Survivin targets the CPC to various locations during cell division by means of its different domains. Survivin's BIR domain localises the CPC to the centromeres, whereas its C-terminus domain localises it to the central spindle and mid-body. 19 At the spindle checkpoint, survivin plays a key role as part of the CPC in retaining the anaphase-promoting complex/cyclosome (APC/C) inhibitor BubR1 at the kinetochores until correct microtubule attachments have been achieved. 20 Survivin also operates independently of the CPC. It binds directly to microtubules in metaphase and anaphase, and is involved in regulation of microtubule dynamics. 21 
Regulation of Survivin

Survivin and Cancer
Survivin is almost undetectable in most adult tissues, and expression is largely limited to developing embryos and haematopoietic, epithelial and gonadal cell lines, where expression is often cell-cycle-dependent. 3 However, survivin over-expression has been reported in nearly all human malignancies. 14 In most cases, this results from non-cell-cycledependent mechanisms driving survivin gene transcription. Three key intracellular pathways converge on the survivin promoter: the phosphatidylinositide 3,4,5-triphosphate kinase (PI3k)/Akt pathway, 28 the Janus kinase (JAK)/Stat-3 pathway 29 and the TCF/β-catenin pathway. 30 The upregulation of these pathways is either in response to growth factors such as epidermal growth factor (EGF), 31 interleukin (IL)-6 or granulocyte-macrophage colony-stimulating factor (GM-CSF), 32 or through downregulation of tumour suppressors such as adenomatous polyposis coli (APC), 33 p53, 34 promyelocytic leukaemia protein (PML)-4 35 and fragile histidine triad gene (FHIT). 36 In fact, all of the best characterised tumour suppressor networks, such as p53, target the survivin gene, thus underscoring survivin's importance in malignancy.
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Methods of Targeting Survivin and Pre-clinical Results
By knocking out survivin, multiple networks of cell proliferation and cytoprotection can be simultaneously disrupted. Direct survivin inhibition has been investigated at several levels: gene transcription, translation and protein degradation. Additionally, gene therapies and immunotherapies are in development (see Figure 2 and Table 1 ). 41 However, another phase II study in 34 chemotherapynaïve patients with unresectable stage III or IV melanoma reported only one PR, thus failing to meet its pre-specified primary end-point for
Transcriptional Inhibition
Survivin-directed Anticancer Therapies -Pre-clinical Data and Early-phase Clinical Trials efficacy of two responders in 29 evaluable patients. 42 EM-1421 is a small-molecule transcription inhibitor that selectively targets the Sp1-dependent promoters of various genes, including CDC2 and survivin. 43 This molecule has reached phase I trials as a vaginal ointment for use in human papillomavirus (HPV)-linked cervical intraepithelial neoplasia, and has an excellent safety profile. 44, 45 Moreover, a systemic formula of EM-1421 has also been developed, with promising antitumour effects in mouse models. 43 
Translational Inhibition
Molecular antagonists including antisense oligonucleotides (ASOs), hammerhead ribozymes and small-interfering mRNA (siRNA) have been developed to target survivin at the level of mRNA translation. Grossman et al. 46 were the first to use a survivin ASO against malignant melanoma cell lines. Transfection with the ASO triggered spontaneous apoptosis, and two-colour flow cytometry confirmed decreased endogenous survivin expression. Other pre-clinical studies confirmed these results 47, 48 and found that survivin downregulation sensitises certain human cancer cell lines to cisplatin and etoposide, 49 as well as to radiotherapy. non-phosphorylatable by p34 cdc2 -cyclin B1 and, consequently, preventing it from inhibiting apoptosis. 60 The introduction of this mutant was shown to trigger spontaneous apoptosis in a number of cancer cell lines, including breast, cervical, prostate, colorectal and melanoma, as well as reducing tumour formation and growth in mouse melanoma and breast cancer models. 61, 62 Another mutant is survivin C84A, in which the cysteine residue is exchanged for alanine in the BIR domain. Survivin C84A displaces wild-type survivin from polymerised microtubules and completely abolishes survivin's antiapoptotic activity. 63 Introduction of this mutant into melanoma and colorectal cell lines caused an increase in apoptosis, 46 ,64 and follow-up Current Issues Novel Therapies in vivo experiments demonstrated that survivin C84A reduced both tumour growth and angiogenesis, as well as enhancing the effects of 5-fluorouracil. 64 Due to the survivin protein's need for Hsp90 for stability, the peptidomimetic Shepherdin was developed to disrupt this interaction by interacting with the ATP-binding pocket on Hsp90.
Early in vitro experiments showed that Shepherdin induces cell death within tumour cells, while sparing normal cells. 65 In both breast cancer and acute myeloid leukaemia (AML) mouse xenograft models, Shepherdin was well-tolerated and inhibited tumour growth. 65, 66 After it was shown that Shepherdin residues 79-83 were essential for 
Immunotherapy
A number of research groups have tested survivin-directed immunological approaches in pre-clinical models. For example, a survivin DNA vaccine was evaluated in murine pancreatic and lymphoma models, and was found to significantly slow tumour growth and prolong survival through increased lymphocyte infiltration at the tumour sites. 74 In an NSCLC mouse model, oral delivery of a DNA vaccine triggered activation of antigen-presenting dendritic cells (DCs) and a cytotoxic T-lymphocyte (CTL) response, which resulted in elimination or suppression of pulmonary metastases. 75 Another group developed a novel mimovirus vaccine, consisting of a cationic peptide containing a survivin CTL epitope and a plasmid encoding the murine IL-15 gene.
The mimovirus was shown to inhibit tumour growth and prolong life in a mouse model. 76 
